{"id":"yohimbine","rwe":[{"pmid":"41847229","year":"2026","title":"Adrenergic receptor activation triggers stress-induced dystonia in a CACNA1A mutant mouse model.","finding":"","journal":"Frontiers in neuroscience","studyType":"Clinical Study"},{"pmid":"41834039","year":"2026","title":"Social defeat stress responses in the stress alternative model are dependent on sex and anterior basolateral amygdala orexin 2 receptors.","finding":"","journal":"Biology of sex differences","studyType":"Clinical Study"},{"pmid":"41810593","year":"2026","title":"Sodium Nitroprusside Potentiates Capsaicin-Activated TRPV1-mediated Relaxation of Goat Detrusor Smooth Muscle.","finding":"","journal":"Neurourology and urodynamics","studyType":"Clinical Study"},{"pmid":"41806910","year":"2026","title":"Vanillin suppresses seizure-induced mortality in the DBA/1 mouse model of SUDEP.","finding":"","journal":"Neuroscience letters","studyType":"Clinical Study"},{"pmid":"41791564","year":"2026","title":"Dexmedetomidine preconditioning attenuates myocardial ischemia/reperfusion-induced arrhythmia in rats by inhibiting K(ATP) channels via imidazoline receptors: A combined animal and in vitro study.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"yohimbine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-2A adrenergic receptor","category":"target"},{"label":"ADRA2A","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"ADRA1B","category":"gene"},{"label":"G04BE04","category":"atc"},{"label":"Active","category":"status"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-2 Receptor Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Mydriatics","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Urological Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":79.646,"date":"","count":12,"signal":"Hypertensive emergency","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=80)"},{"llr":62.617,"date":"","count":14,"signal":"Haemorrhage intracranial","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=63)"}],"commonSideEffects":[{"effect":"Hypertensive emergency","drugRate":"LLR 80","severity":"common"},{"effect":"Haemorrhage intracranial","drugRate":"LLR 63","severity":"common"}],"contraindications":["Angina pectoris","Depressive disorder","Disease of liver","Heart disease","Hypocupremia","Kidney disease","Low blood pressure","Psychiatric Disturbance"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"yohimbin","offLabel":[],"synonyms":["yohimbine","yohimbin","quebrachin","quebrachine","yohimbine hydrochloride","yohimbine HCl"],"timeline":[],"aiSummary":"Yohimbine, also known as YOHIMBINE, is a small molecule drug that targets the alpha-2A adrenergic receptor. It is classified as a yohimbine drug and its mechanism of action is not FDA approved for any indications. Yohimbine has a half-life of 1.5 hours and bioavailability of 33%. The commercial status of Yohimbine is unknown, and it is not approved for any specific indications. As a result, its use is largely off-label and requires careful consideration of its potential risks and benefits.","approvals":[{"date":"","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Yohimbin","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","novelty":"First-in-class","targets":[{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"HTR1B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1B","protein":"5-hydroxytryptamine receptor 1B"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"}],"modality":"Small Molecule","drugClass":"yohimbine","explanation":"Imagine your brain has a 'brake' that helps you relax and calm down. Yohimbine is like a key that unlocks this brake, allowing your brain to send more signals to your body to be more alert and active. This can be helpful for people who need a boost of energy or focus, but it can also have negative effects if not used carefully.","oneSentence":"Yohimbine works by blocking the alpha-2A adrenergic receptor, which increases the release of norepinephrine and epinephrine, leading to increased alertness and energy.","technicalDetail":"Yohimbine acts as a competitive antagonist at the alpha-2A adrenergic receptor, which is a subtype of adrenergic receptor that is involved in the regulation of sympathetic nervous system activity. By blocking this receptor, yohimbine increases the release of norepinephrine and epinephrine, leading to increased sympathetic nervous system activity and a range of physiological effects, including increased heart rate, blood pressure, and alertness."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3659","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=YOHIMBINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=YOHIMBINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:15:30.345569","biosimilars":[],"competitors":[{"drugName":"alprostadil","drugSlug":"alprostadil","fdaApproval":"1981-10-16","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"papaverine","drugSlug":"papaverine","fdaApproval":"","relationship":"same-class"},{"drugName":"sildenafil","drugSlug":"sildenafil","fdaApproval":"1998-03-27","patentExpiry":"Dec 24, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tadalafil","drugSlug":"tadalafil","fdaApproval":"2003-11-21","patentExpiry":"Dec 24, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"vardenafil","drugSlug":"vardenafil","fdaApproval":"2003-08-19","patentExpiry":"Jul 23, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"avanafil","drugSlug":"avanafil","fdaApproval":"2012-04-27","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"yohimbine","indications":{"approved":[],"offLabel":[{"name":"Impotence","source":"DrugCentral","drugName":"YOHIMBINE","evidenceCount":233,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alprostadil","brandName":"alprostadil","genericName":"alprostadil","approvalYear":"1981","relationship":"same-class"},{"drugId":"papaverine","brandName":"papaverine","genericName":"papaverine","approvalYear":"","relationship":"same-class"},{"drugId":"sildenafil","brandName":"sildenafil","genericName":"sildenafil","approvalYear":"1998","relationship":"same-class"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-class"},{"drugId":"tadalafil","brandName":"tadalafil","genericName":"tadalafil","approvalYear":"2003","relationship":"same-class"},{"drugId":"vardenafil","brandName":"vardenafil","genericName":"vardenafil","approvalYear":"2003","relationship":"same-class"},{"drugId":"avanafil","brandName":"avanafil","genericName":"avanafil","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06939608","phase":"NA","title":"Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2025-04-28","conditions":["Pharmacokinetic Study in Healthy Volunteers"],"enrollment":36,"completionDate":"2025-10-10"},{"nctId":"NCT04231708","phase":"PHASE2","title":"Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Wayne State University","startDate":"2026-10","conditions":["Opioid Use Disorder"],"enrollment":20,"completionDate":"2028-12"},{"nctId":"NCT05755490","phase":"NA","title":"PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2023-08-28","conditions":["Prostate Cancer","Prostatic Neoplasms"],"enrollment":14,"completionDate":"2025-09-29"},{"nctId":"NCT06430580","phase":"EARLY_PHASE1","title":"Cannabinoids and Biological Reactivity to Stress","status":"RECRUITING","sponsor":"Florida State University","startDate":"2024-09-30","conditions":["Cannabis Use Disorder"],"enrollment":36,"completionDate":"2026-09-30"},{"nctId":"NCT03520543","phase":"PHASE1","title":"[11C]Yohimbine PET Study of alpha2-AR","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-05-21","conditions":["Healthy Controls"],"enrollment":16,"completionDate":"2019-01-21"},{"nctId":"NCT07127146","phase":"NA","title":"Opioidergic and Noradrenergic Systems in Central Parkisonian Pain","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-01","conditions":["Parkinson Disease"],"enrollment":55,"completionDate":"2025-10-01"},{"nctId":"NCT02243709","phase":"PHASE1,PHASE2","title":"Mifepristone for the Prevention of Relapses of Alcohol Drinking","status":"COMPLETED","sponsor":"Brown University","startDate":"2014-09","conditions":["Alcohol Use Disorders (AUD)"],"enrollment":32,"completionDate":"2021-12-21"},{"nctId":"NCT06018727","phase":"PHASE4","title":"Role Of Sensitivity to neuroEndocrine Systems in Social Decisions","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-07","conditions":["Borderline Personality Disorder"],"enrollment":0,"completionDate":"2025-07"},{"nctId":"NCT03154567","phase":"PHASE1","title":"Effects of Stress and Drug-cue Exposure (SCM)","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2017-11-01","conditions":["Marijuana Abuse"],"enrollment":12,"completionDate":"2023-10-27"},{"nctId":"NCT06199778","phase":"NA","title":"Effect of Intermittent Oro-esophageal Tube Feeding on Severe Traumatic Brain Injury Patients With Tracheostomy","status":"TERMINATED","sponsor":"Zeng Changhao","startDate":"2022-06-01","conditions":["Traumatic Brain Injury"],"enrollment":104,"completionDate":"2023-06-15"},{"nctId":"NCT04346394","phase":"EARLY_PHASE1","title":"The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease","status":"WITHDRAWN","sponsor":"Nathaniel M. Robbins","startDate":"2021-05-11","conditions":["Parkinson Disease"],"enrollment":0,"completionDate":"2023-08-01"},{"nctId":"NCT04180969","phase":"PHASE2","title":"rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers","status":"WITHDRAWN","sponsor":"Wayne State University","startDate":"2023-04-10","conditions":["Stress","Healthy"],"enrollment":0,"completionDate":"2023-04-10"},{"nctId":"NCT04181515","phase":"PHASE2","title":"Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use","status":"WITHDRAWN","sponsor":"Wayne State University","startDate":"2023-04-10","conditions":["Stress","Opioid-use Disorder"],"enrollment":0,"completionDate":"2023-04-10"},{"nctId":"NCT04359147","phase":"NA","title":"The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2019-11-01","conditions":["Yohimbine","Hydrocortisone","Yohimbine + Hydrocortisone","Placebo"],"enrollment":167,"completionDate":"2021-12-22"},{"nctId":"NCT03223272","phase":"PHASE2","title":"Mechanisms of Refractory Hypertension (Reserpine)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-07-23","conditions":["Refractory Hypertension"],"enrollment":7,"completionDate":"2020-01-31"},{"nctId":"NCT00748059","phase":"PHASE1","title":"The Pathophysiology of Orthostatic Hypotension","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"1996-12","conditions":["Autonomic Nervous System Diseases","Orthostatic Hypotension","Dopamine Beta-Hydroxylase Deficiency","Orthostatic Intolerance"],"enrollment":10,"completionDate":"2020-12"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT03015246","phase":"PHASE1,PHASE2","title":"Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-12","conditions":["Heroin Dependence","Opioid Use Disorder"],"enrollment":26,"completionDate":"2020-08"},{"nctId":"NCT00078715","phase":"PHASE2","title":"Rapid Antidepressant Effects of Yohimbine in Major Depression","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2004-03","conditions":["Depression, Involutional","Major Depresssion"],"enrollment":11,"completionDate":"2009-08"},{"nctId":"NCT03942289","phase":"NA","title":"Human Aging and in Vivo Noradrenergic System","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2019-04-29","conditions":["Parkinson Disease"],"enrollment":135,"completionDate":"2021-06-29"},{"nctId":"NCT02963181","phase":"EARLY_PHASE1","title":"Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2018-03-01","conditions":["Hypotension, Orthostatic","Hypertension","Autonomic Nervous System Diseases"],"enrollment":10,"completionDate":"2019-05-28"},{"nctId":"NCT02470026","phase":"NA","title":"Noradrenergic Activity, Cognition and Major Depressive Disorder","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-06","conditions":["Major Depressive Disorder","Early Life Trauma"],"enrollment":131,"completionDate":"2018-10"},{"nctId":"NCT02684786","phase":"PHASE1","title":"A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2016-07","conditions":["Pulmonary Artery Hypertension"],"enrollment":0,"completionDate":"2016-07"},{"nctId":"NCT00734422","phase":"PHASE2,PHASE3","title":"Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants","status":"COMPLETED","sponsor":"VU University of Amsterdam","startDate":"2008-07","conditions":["Phobic Disorders"],"enrollment":67,"completionDate":"2010-07"},{"nctId":"NCT03670212","phase":"PHASE1","title":"Investigation of Nicotine Seeking Behavior in Current Smokers","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2016-01-07","conditions":["Cigarette Smoking"],"enrollment":21,"completionDate":"2016-10-04"},{"nctId":"NCT01536925","phase":"","title":"Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2011-12","conditions":["Heroin Dependence","Opioid-Related Disorders"],"enrollment":21,"completionDate":"2017-04"},{"nctId":"NCT01031979","phase":"PHASE2","title":"Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-12-01","conditions":["Post-Traumatic Stress Disorder"],"enrollment":26,"completionDate":"2015-07-07"},{"nctId":"NCT00103987","phase":"","title":"Neurobiological Mechanisms in Panic Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2005-02-14","conditions":["Panic Disorder"],"enrollment":54,"completionDate":"2010-11-12"},{"nctId":"NCT00109642","phase":"","title":"The Role of Norepinephrine in Emotional Processing","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2005-04-26","conditions":["Psychopathy","Mental Disorders"],"enrollment":216,"completionDate":"2009-03-15"},{"nctId":"NCT00535002","phase":"PHASE2","title":"The Effect of Yohimbine on Cocaine Cue Reactivity","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-09","conditions":["Cocaine Related Disorders"],"enrollment":112,"completionDate":"2012-08"},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":["Autonomic Failure","Orthostatic Hypotension"],"enrollment":389,"completionDate":"2017-01"},{"nctId":"NCT00033033","phase":"PHASE2","title":"Reserpine for the Treatment of Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-07","conditions":["Cocaine-Related Disorders","Substance-Related Disorders"],"enrollment":140,"completionDate":"2003-05"},{"nctId":"NCT00267657","phase":"PHASE1","title":"A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2004-01","conditions":["Amphetamine-Related Disorders"],"enrollment":30,"completionDate":"2004-11"},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":["Atherosclerosis","Cardiovascular Diseases","Hypercholesterolemia","Hypertension","Diabetes Mellitus, Type 2","Diabetes Mellitus","Coronary Disease"],"enrollment":10251,"completionDate":"2012-12"},{"nctId":"NCT00000514","phase":"PHASE3","title":"Systolic Hypertension in the Elderly Program (SHEP)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1984-06","conditions":["Cardiovascular Diseases","Cerebrovascular Disorders","Heart Diseases","Hypertension"],"enrollment":0,"completionDate":"1996-10"},{"nctId":"NCT02578849","phase":"","title":"Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia","status":"UNKNOWN","sponsor":"Aarhus University Hospital","startDate":"2012-01","conditions":["Parkinson´s Disease"],"enrollment":45,"completionDate":"2016-01"},{"nctId":"NCT02541071","phase":"NA","title":"Influence of the Noradrenergic System on the Formation of Intrusive Memories","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2013-11","conditions":["Intrusive Memories"],"enrollment":118,"completionDate":"2014-10"},{"nctId":"NCT02007694","phase":"PHASE2,PHASE3","title":"Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants","status":"COMPLETED","sponsor":"VU University of Amsterdam","startDate":"2013-03","conditions":["Phobic Disorders"],"enrollment":56,"completionDate":"2014-12"},{"nctId":"NCT00975325","phase":"PHASE4","title":"Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine","status":"COMPLETED","sponsor":"Walter Ritter GmbH & Co","startDate":"2009-10","conditions":["Erectile Dysfunction"],"enrollment":42,"completionDate":"2010-12"},{"nctId":"NCT01593215","phase":"PHASE2","title":"Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant","status":"COMPLETED","sponsor":"Anders Rosengren, MD PhD","startDate":"2012-05","conditions":["Type 2 Diabetes"],"enrollment":50,"completionDate":"2014-10"},{"nctId":"NCT00000499","phase":"PHASE2","title":"Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1980-09","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Vascular Diseases"],"enrollment":0,"completionDate":"1983-05"},{"nctId":"NCT00958880","phase":"PHASE3","title":"Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety","status":"COMPLETED","sponsor":"Southern Methodist University","startDate":"2009-03","conditions":["Social Anxiety Disorder"],"enrollment":40,"completionDate":"2013-01"},{"nctId":"NCT00605904","phase":"PHASE2","title":"Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2008-01","conditions":["Alcoholism"],"enrollment":37,"completionDate":"2011-03"},{"nctId":"NCT01621620","phase":"NA","title":"The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2012-08","conditions":["Pain"],"enrollment":20,"completionDate":"2014-08"},{"nctId":"NCT00217048","phase":"PHASE1,PHASE2","title":"Effect of Yohimbine on Colon Transit","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-06","conditions":["Healthy Volunteers"],"enrollment":30,"completionDate":"2005-10"},{"nctId":"NCT00814047","phase":"PHASE4","title":"The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"","conditions":["Blood Flow Velocity","Autoregulation","Ocular Physiology"],"enrollment":18,"completionDate":""},{"nctId":"NCT00042536","phase":"","title":"Effects of Yohimbine and Naltrexone on Sexual Function","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-07","conditions":["Erectile Dysfunction"],"enrollment":40,"completionDate":"2004-04"},{"nctId":"NCT00032838","phase":"","title":"Effects of Stress Hormones on Emotion and Cognition","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-03","conditions":["Healthy"],"enrollment":170,"completionDate":"2006-01"},{"nctId":"NCT00001329","phase":"","title":"Study of Norepinephrine Levels and Sympathetic Nervous System Activity","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1992-09","conditions":["Autonomic Nervous System Disease","Healthy","Hypertension"],"enrollment":50,"completionDate":"2002-09"},{"nctId":"NCT00029627","phase":"","title":"Brain Receptors in Sympathetic Nervous System Regulation","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-01","conditions":["Healthy"],"enrollment":200,"completionDate":"2004-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000020654","MMSL":"1391","NDDF":"002414","UNII":"2Y49VWD90Q","VUID":"4022649","CHEBI":"CHEBI:10093","VANDF":"4018920","RXNORM":"133041","UMLSCUI":"C0724441","ChEMBL_ID":"CHEMBL15245","KEGG_DRUG":"D06671","DRUGBANK_ID":"DB01392","PUBCHEM_CID":"8969","SNOMEDCT_US":"398674007","IUPHAR_LIGAND_ID":"102","SECONDARY_CAS_RN":"65-19-0","MESH_DESCRIPTOR_UI":"D015016"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.5 hours","clearance":"14.6 mL/min/kg","bioavailability":"33%","fractionUnbound":"0.2%","volumeOfDistribution":"0.48 L/kg"},"publicationCount":8012,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"G04BE04","allCodes":["G04BE04"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41847229","title":"Adrenergic receptor activation triggers stress-induced dystonia in a CACNA1A mutant mouse model.","journal":"Frontiers in neuroscience"},{"date":"2026 Mar 15","pmid":"41834039","title":"Social defeat stress responses in the stress alternative model are dependent on sex and anterior basolateral amygdala orexin 2 receptors.","journal":"Biology of sex differences"},{"date":"2026 Mar 11","pmid":"41810593","title":"Sodium Nitroprusside Potentiates Capsaicin-Activated TRPV1-mediated Relaxation of Goat Detrusor Smooth Muscle.","journal":"Neurourology and urodynamics"},{"date":"2026 Mar 8","pmid":"41806910","title":"Vanillin suppresses seizure-induced mortality in the DBA/1 mouse model of SUDEP.","journal":"Neuroscience letters"},{"date":"2026 Mar 28","pmid":"41791564","title":"Dexmedetomidine preconditioning attenuates myocardial ischemia/reperfusion-induced arrhythmia in rats by inhibiting K(ATP) channels via imidazoline receptors: A combined animal and in vitro study.","journal":"European journal of pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}